Allogene Therapeutics Inc

NASDAQ:ALLO   3:59:50 PM EDT
25.65
-1.99 (-7.20%)
Products

Allogene Therapeutics Receives FDA ODD For ALLO-715

Published: 08/12/2021 12:56 GMT
Allogene Therapeutics Inc (ALLO) - Allogene Therapeutics Receives FDA Orphan Drug Designation (odd) for Allo-715 for the Treatment of Multiple Myeloma (mm).
Allogene Therapeutics Inc - Next Clinical Update From Allo-715 Universal Trial Planned for Late 2021.
Allogene Therapeutics Inc - Odd Follows Rmat Designation Granted to Allo-715 by FDA in Multiple Myeloma Patients.